Last reviewed · How we verify

bepotastine besilate ophthalmic solution — Competitive Intelligence Brief

bepotastine besilate ophthalmic solution (bepotastine besilate ophthalmic solution) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed H1-receptor, mast cells Small molecule Live · refreshed every 30 min

Target snapshot

bepotastine besilate ophthalmic solution (bepotastine besilate ophthalmic solution) — Bausch & Lomb Incorporated. Bepotastine blocks H1 receptors and inhibits histamine release from mast cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
bepotastine besilate ophthalmic solution TARGET bepotastine besilate ophthalmic solution Bausch & Lomb Incorporated marketed H1-receptor, mast cells
Bepreve BEPOTASTINE Bausch Health marketed Histamine-1 Receptor Antagonist H1-receptor, mast cells 2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bepotastine besilate ophthalmic solution — Competitive Intelligence Brief. https://druglandscape.com/ci/bepotastine-besilate-ophthalmic-solution. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: